Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Celestone Soluspan

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
B B
B B

Betametason - systemiskt Testmiljö

Betametason - systemiskt

Klass : B

Visa all info

Skriv ut

Kontakta oss

  1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.

  2. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14:177-86.

  3. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54.

  4. Petersen MC, Nation RL, McBride WG, Ashley JJ, Moore RG. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur J Clin Pharmacol 1983;25(5):643-50

  5. The United Kingdom Teratology Information Service (UKTIS) - Exposure in pregnancy. Corticosteroids in pregnancy. Newcastle upon Tyne: Public Health England. 2012 [cited 2016-09-15.]

  6. Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev. 2015;7:CD003935.

  7. Roberge S, Lacasse Y, Tapp S, Tremblay Y, Kari A, Liu J et al. Role of fetal sex in the outcome of antenatal glucocorticoid treatment to prevent respiratory distress syndrome: systematic review and meta-analysis. J Obstet Gynaecol Can. 2011;33:216-26.

  8. Ballard PL, Ballard RA, Granberg JP, Sniderman S, Gluckman PD, Kaplan SL et al. Fetal sex and prenatal betamethasone therapy. J Pediatr. 1980;97:451-4.

  9. Papageorgiou AN, Colle E, Farri-Kostopoulos E, Gelfand MM. Incidence of respiratory distress syndrome following antenatal betamethasone: role of sex, type of delivery, and prolonged rupture of membranes. Pediatrics. 1981;67:614-7.

  10. Alexander N, Rosenlöcher F, Dettenborn L, Stalder T, Linke J, Distler W et al. Impact of Antenatal Glucocorticoid Therapy and Risk of Preterm Delivery on Intelligence in Term-Born Children. J Clin Endocrinol Metab. 2016;101:581-9.

  11. Dessens AB, Haas HS, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics. 2000;105:E77.

  12. Eriksson L, Haglund B, Ewald U, Odlind V, Kieler H. Short and long-term effects of antenatal corticosteroids assessed in a cohort of 7,827 children born preterm. Acta Obstet Gynecol Scand. 2009;88:933-8.

  13. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-09-15.]

  14. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]

  1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.
  2. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14:177-86.
  3. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54.
  4. Petersen MC, Nation RL, McBride WG, Ashley JJ, Moore RG. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur J Clin Pharmacol 1983;25(5):643-50
  5. The United Kingdom Teratology Information Service (UKTIS) - Exposure in pregnancy. Corticosteroids in pregnancy. Newcastle upon Tyne: Public Health England. 2012 [cited 2016-09-15.]
  6. Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev. 2015;7:CD003935.
  7. Roberge S, Lacasse Y, Tapp S, Tremblay Y, Kari A, Liu J et al. Role of fetal sex in the outcome of antenatal glucocorticoid treatment to prevent respiratory distress syndrome: systematic review and meta-analysis. J Obstet Gynaecol Can. 2011;33:216-26.
  8. Ballard PL, Ballard RA, Granberg JP, Sniderman S, Gluckman PD, Kaplan SL et al. Fetal sex and prenatal betamethasone therapy. J Pediatr. 1980;97:451-4.
  9. Papageorgiou AN, Colle E, Farri-Kostopoulos E, Gelfand MM. Incidence of respiratory distress syndrome following antenatal betamethasone: role of sex, type of delivery, and prolonged rupture of membranes. Pediatrics. 1981;67:614-7.
  10. Alexander N, Rosenlöcher F, Dettenborn L, Stalder T, Linke J, Distler W et al. Impact of Antenatal Glucocorticoid Therapy and Risk of Preterm Delivery on Intelligence in Term-Born Children. J Clin Endocrinol Metab. 2016;101:581-9.
  11. Dessens AB, Haas HS, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics. 2000;105:E77.
  12. Eriksson L, Haglund B, Ewald U, Odlind V, Kieler H. Short and long-term effects of antenatal corticosteroids assessed in a cohort of 7,827 children born preterm. Acta Obstet Gynecol Scand. 2009;88:933-8.
  13. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-09-15.]
  14. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]